OraSure Technologies Inc (OSUR) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of OraSure Technologies Inc $2.90, price $3.99, upside -27.3%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch OraSure Technologies Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.11 – $13.38 · fair‑value band $1.91 – $3.62 · the $3.99 price screens above the $2.90 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow OraSure Technologies in your weekly email
Every Wednesday you see whether OraSure Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.
Show more
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Stock analysis
OraSure Technologies Inc (OSUR) currently trades at $3.99, while our model-based Fair Value estimate is $2.90, implying the stock looks roughly 37.6% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $1.91 (bear) to $3.62 (bull), the price of $3.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
OraSure Technologies Inc reported revenue of $115M in FY2025 versus $234M in FY2021, a compound −16.2%/yr. Reported net income was −$68.7M in FY2025.
Key figures
Market cap $293M · P/S ratio 2.59 · EPS (TTM) $−1.05 · Net margin −59.8% · Return on equity −21.2% · Return on assets (EBIT) −2.7% · Operating margin −78.5% · Revenue (TTM) $113M.
What moves the price
The share trades about 13% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −27%, OSUR screens richer than that median.
Fair Value models
Bear $1.91Fair Value $2.90Bull $3.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−38.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Start year 2020 (pandemic). Over 10 years: −0.4% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.4% (2020) → −59.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare OraSure Technologies Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−27% · Below median
Profitability
Return on assets−11% · Bottom 25%
Net margin (TTM)−66% · Bottom 25%
Operating margin (TTM)−78% · Bottom 25%
Growth and dividend
Revenue growth−7% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.86× · Cheapest 25%
P/S (TTM)2.59× · Pricier than median
PEG6.19× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is OraSure Technologies Inc (OSUR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.90 versus a price of $3.99, about −27% upside (overvalued).
What is the fair value of OSUR?
Our model-based fair value for OraSure Technologies Inc is $2.90 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.99.
What is the quality score of OSUR?
OraSure Technologies Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OraSure Technologies Inc (OSUR)?
Our model-based price target is the fair value of $2.90 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.91, optimistic scenario $3.62. It is a calculation from audited fundamentals, not an analyst target.
What is the OraSure Technologies Inc stock forecast for 2026?
Our models put fair value at $2.90, about −27% upside versus a price of $3.99 (overvalued). Cautious scenario $1.91, optimistic scenario $3.62. The calculation is refreshed regularly with new filings.
What is the revenue of OraSure Technologies Inc (OSUR)?
OraSure Technologies Inc reported trailing-twelve-month revenue of about $113M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of OraSure Technologies Inc (OSUR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OraSure Technologies Inc it is $2.90 per share (as of Sep 24, 2026), against a price of $3.99. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is OraSure Technologies Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, OSUR trades above its calculated fair value: price $3.99, fair value $2.90, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OSUR?
No. The price is what the market pays today ($3.99); the fair value is what the company's own numbers justify ($2.90). For OraSure Technologies Inc the two are $1.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is OraSure Technologies Inc worth?
The market values OraSure Technologies Inc at about $293M (market capitalisation, as of Sep 24, 2026). Per share that is $3.99; our models calculate a fair value of $2.90 per share.
What do the bullish and bearish scenarios say about OSUR?
Our models span a range for OraSure Technologies Inc: cautious scenario $1.91, base $2.90, optimistic $3.62 per share (as of Sep 24, 2026, price $3.99). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of OSUR?
The PEG ratio of OraSure Technologies Inc is 6.19 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of OraSure Technologies Inc (OSUR)?
Balance-sheet figures for OraSure Technologies Inc (as of Sep 24, 2026): return on equity −21.2%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is OSUR from its 52-week high?
OraSure Technologies Inc trades at $3.99, about 13% below its 52-week high of $4.58 and 92% above the low of $2.08 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $2.90 is for.
Which stocks are comparable to OraSure Technologies Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OraSure Technologies Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.99, calculated fair value $2.90 (−27%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OSUR calculated?
We run OraSure Technologies Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. OraSure Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OraSure Technologies Inc (OSUR)?
The closing price on Sep 22, 2026 was $3.99. Our model-based fair value is $2.90, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OraSure Technologies Inc right now?
The price sits above even our optimistic bull case ($3.62). The favourable scenario is already priced in. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.91 to $3.62) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of OraSure Technologies Inc
How large is the market capitalisation of OraSure Technologies Inc (OSUR)?
The market capitalisation of OraSure Technologies Inc is $293M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OraSure Technologies Inc (OSUR)?
The price-to-sales ratio of OraSure Technologies Inc is 2.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OraSure Technologies Inc (OSUR)?
Earnings per share at OraSure Technologies Inc are $−1.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of OraSure Technologies Inc (OSUR)?
The net margin of OraSure Technologies Inc is −59.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OraSure Technologies Inc (OSUR)?
The return on equity (ROE) of OraSure Technologies Inc is −21.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OraSure Technologies Inc (OSUR)?
On an EBIT basis the return on assets of OraSure Technologies Inc is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OraSure Technologies Inc (OSUR)?
The operating margin of OraSure Technologies Inc is −78.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OraSure Technologies Inc (OSUR)?
Revenue at OraSure Technologies Inc is growing −6.7% versus a year earlier (3y avg −33.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OraSure Technologies Inc (OSUR)?
Earnings per share at OraSure Technologies Inc are growing +29.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does OraSure Technologies Inc (OSUR) generate?
The free cash flow of OraSure Technologies Inc is −$53.2K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OraSure Technologies Inc (OSUR) hold?
OraSure Technologies Inc holds more cash than debt, $186M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch OraSure Technologies Inc in the live analysis
One click puts OraSure Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026